Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients (Q46235323)

20 December 2017

title

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients (English)

1 reference

20 December 2017

1 reference

1 reference

Robert S Rosenson

1

1 reference

20 December 2017

publication date

20 November 2008

1 reference

20 December 2017

published in

Obesity

1 reference

20 December 2017

volume

17

1 reference

20 December 2017

page(s)

504-509

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adiponectin and future coronary heart disease events among men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Nuclear factor-kappaB: its role in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adiponectin and cardiovascular disease: response to therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.530

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2008.530

1 reference

20 December 2017

PubMed ID

19023279

1 reference

20 December 2017